E-DRUG: IP and generics in Europe
In case you have not seen this, I draw your
attention to the recent report of the EGA on IP and generic competition
PATENT-RELATED BARRIERS TO MARKET ENTRY FOR GENERIC MEDICINES IN THE
EUROPEAN UNION: A review of weaknesses in the current European patent system
and their impact on the market access of generic medicines
Patents play an important role in modern society, encouraging the creation,
dissemination and efficient exploitation of new technology.
Generic medicines play an equally important role in promoting pharmaceutical
innovation, affordability and sustainability. Immediate market access of
generic medicines after patent expiry is crucial to society.
When patents?of sometimes questionable quality?are misused merely to prevent
others from innovating and competing, they can present a formidable barrier to
entry onto the generic medicines market.
This report identifies some of the patent-related hurdles facing generic
medicines in the European Union.
see the full report and presse release at
Kees de Joncheere
Regional Adviser Health Technology and Pharmaceuticals
WHO Regional office for Europe
8 Scherfigsvej, 2100 Copenhagen, Denmark